Hi fellow Fools,The PDUFA date for Cabo is only a span of 2 weeks away – let’s have our fingers crossed!At the Exelixis, Inc. (EXEL) Lazard Capital Markets 9th Annual Healthcare Conference Call November 14, 2012 Frank L. Karbe (Executive Vice President and Chief Financial Officer) gave some information regarding the clinical development of cabozantinib which I will comment today in my next post on this board.http://seekingalpha.com/article/1008091-exelixis-management-...PipelineAt the end of the presentation Karbe gave some insight into the terms of the co-operation with Roche/Genentech (GDC-0973 / XL518) – anwering some ot the questions I have raised in my previous post on this bard. Ouote:<< We participate 50-50 on the first 200 million of actual U.S. sales then sort of declines to 30% profit share for actual sales about 400 million. Outside of the U.S., we are eligible to receive low double-digit royalties. And so overall I think the economic stake that we have here is quite attractive.Beyond that we also have a co-promotion option, which allows us to potentially fill up to 25% of total sales force for GC-0973. This option must be exercised within 12 months of receiving notification of the first patient being dosed in the pivotal study. Now if you look at ClinicalTrials.gov, you will see that the pivotal study is up and running. >>As you see Exelixis must fill up 25% of total sales force within one year from now – cost implication?Broad pipeline:Outside of cabo, Exelixis has a fairly broad pipeline of partnered assets - future gems?.1) GDC-0973 / XL518 2) Two PI3K inhibitors XL147 and XL765, which are in collaboration with Sanofi3) XL880 similar compound to Cabo (also VEGF and MET inhibitor), partnered with GSK.Update on cabo’ clinical development plan will follow soon…Fool onmarsuculix, who is still very optimistic and thinks that his investment will give him sweet fruits!
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat